Suven Life Sciences Board of Directors
Get the latest insights into the leadership at Suven Life Sciences. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Venkateswarlu Jasti | Chairman & Managing Director |
| Mrs. Sudharani Jasti | Whole Time Director |
| Prof. Seyed E Hasnain | Director |
| Mr. Santanu Mukherjee | Director |
| Mrs. J A S Padmaja | Director |
| Dr. Vajja Sambasiva Rao | Director |
Suven Life Sciences Share price
SUVEN
149.45
1.50 (-0.99%)NSE
BSE
Last updated on 24 Feb, 2026 | 15:29 IST
BUYSELL
Today's High
152.39
Today's Low
145.60
52 Week Low
102.50
52 Week High
299.99
Free Demat with Zero AMC*
Suven Life Sciences FAQs
The board at Suven Life Sciences consists of experienced professionals, including Mr. Venkateswarlu Jasti , Mrs. Sudharani Jasti , and others, overseeing the company’s strategic and corporate governance.
Directors at Suven Life Sciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Venkateswarlu Jasti is the current chairman at Suven Life Sciences.
Executive directors at Suven Life Sciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Suven Life Sciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Suven Life Sciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
